TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Noramco Forges Strategic Partnership with Purisys and Halo Pharma, Creating Integrated North American API and Drug Product Supply Chain Services Provider

Saturday, March 16, 2024

Noramco, a major global manufacturer of active pharmaceutical ingredients (APIs) specializing in controlled substances, has announced the establishment of the Noramco Group. This new entity brings together subsidiaries Purisys, Noramco, and recently acquired drug product CDMO, Halo Pharma, to offer a comprehensive supply chain solution based in North America. This strategic integration aims to address the growing concerns of drug shortages and quality issues affecting patient access, particularly in the United States.

The current challenges, exacerbated by unreliable foreign supply chains, limited domestic manufacturing capacity, and logistical hurdles, have underscored the vulnerabilities of the pharmaceutical supply network. The COVID-19 pandemic has further highlighted the risks associated with reliance on overseas manufacturing, prompting Noramco to advocate for enhanced supply chain performance and increased domestic production.

Lee Karras, CEO of the Noramco Group, highlighted the significance of this initiative, stating, "The COVID-19 pandemic has exposed critical weaknesses in our drug supply chain. While governmental responses have been made, they haven't fully addressed the underlying issues. The Noramco Group aims to proactively tackle these challenges by providing a comprehensive, North American-based supply chain solution. Leveraging our advanced manufacturing capabilities, rigorous quality control measures, and timely delivery, we strive to mitigate the risks of drug shortages and ensure a stable supply of essential APIs and drug products."

Noramco, headquartered in Wilmington, Delaware, serves as a global supplier of commercial APIs, supporting various medical treatments such as pain management and drug abuse treatment. Purisys, located in Athens, Georgia, specializes in clinical API development and manufacturing, focusing on controlled substances and pharmaceutical reference standards. Halo Pharma, operating in Whippany, New Jersey, and Montreal, Quebec, is a contract development and manufacturing organization (CDMO) offering manufacturing services for diverse dosage forms.

The consolidation of these entities is expected to streamline industry processes, reduce logistics costs, and enhance regulatory compliance. Notably, it offers benefits such as intellectual property protection from a domestic source, particularly advantageous for pharma and biotech companies working with New Chemical Entities (NCEs). Furthermore, the integrated API and drug product CDMO services in North America could open up opportunities for securing government grants and contracts.

This strategic move positions the Noramco Group as a leader in ensuring the reliability of the U.S. pharmaceutical supply chain. For inquiries about how the Noramco Group can support API to drug product supply needs, please visit www.noramco.com. Additionally, executives from the Noramco Group will be available at DCAT Week, March 18-21, 2024, in New York City, or you can contact them online for customized solutions-oriented approaches to clinical trial material delivery and commercial scale delivery of APIs and finished dose forms.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit